Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch To Rituximab in Multiple Sclerosis (Extension)
2013-002378-26Phase 2Completed
- Sponsor
- Region Västerbotten
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Region Västerbotten. Primary endpoint: Feasibility and safety of switching to rituximab. Started Aug 2013; status: completed.
02
Drugs
rituximab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2013-002378-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002378-26.